What is Veracyte?
Veracyte is a genomic diagnostics company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Genomic diagnostics company
- Headquarters
- South San Francisco, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: VCYT
What is Veracyte?
Veracyte is a genomic diagnostics company company headquartered in South San Francisco, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Veracyte is a genomic diagnostics company company headquartered in South San Francisco, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Veracyte should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Veracyte offer?
Veracyte's profile centers on Genomic diagnostics, Cancer diagnostics, Pulmonology tests, Thyroid tests.
- Genomic diagnostics· Genomic diagnostics company
- Cancer diagnostics· Genomic diagnostics company
- Pulmonology tests· Genomic diagnostics company
- Thyroid tests· Genomic diagnostics company
- Lab services· Genomic diagnostics company
- Clinical evidence· Genomic diagnostics company
How does Veracyte make money?
Veracyte makes money through commercial activity tied to genomic diagnostics company.
Veracyte monetizes through the model common to genomic diagnostics company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Veracyte?
Veracyte's named executives should be verified on the official leadership or investor-relations page before outreach.
- Veracyte executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Veracyte finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Veracyte operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Veracyte's leadership?
Veracyte should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.veracyte.com- Veracyte investor relationsInvestor relations / corporate contactcontact via https://www.veracyte.com
How is Veracyte funded?
Veracyte's current status is Public company; Nasdaq: VCYT.
Veracyte's capital profile is best understood through its current public-company status: Public company; Nasdaq: VCYT. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Veracyte get here?
Veracyte's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingVeracyte is foundedThe company begins building in genomic diagnostics company.
- Scale-upCommercial footprint expandsVeracyte broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: VCYTPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Veracyte's competitors?
Veracyte competes with larger incumbents and focused specialists in genomic diagnostics company.
Veracyte — frequently asked questions
